Tyme Technologies Inc (NASDAQ:TYME) major shareholder Michael Demurjian sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $1.14, for a total value of $22,800.00. Following the completion of the transaction, the insider now directly owns 26,330,521 shares in the company, valued at $30,016,793.94. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Michael Demurjian also recently made the following trade(s):

  • On Monday, August 26th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.10, for a total value of $22,000.00.
  • On Monday, August 19th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.03, for a total value of $20,600.00.
  • On Monday, August 12th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.00, for a total value of $20,000.00.
  • On Monday, August 5th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.12, for a total value of $22,400.00.
  • On Monday, July 29th, Michael Demurjian sold 50,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.11, for a total value of $55,500.00.
  • On Monday, July 22nd, Michael Demurjian sold 50,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.18, for a total value of $59,000.00.

Shares of TYME traded up $0.02 during mid-day trading on Friday, hitting $1.25. 511,469 shares of the stock were exchanged, compared to its average volume of 336,938. Tyme Technologies Inc has a 52-week low of $0.92 and a 52-week high of $4.64. The firm has a 50-day moving average of $1.12 and a two-hundred day moving average of $1.52.

Tyme Technologies (NASDAQ:TYME) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.02. On average, sell-side analysts expect that Tyme Technologies Inc will post -0.22 earnings per share for the current year.

Institutional investors and hedge funds have recently modified their holdings of the company. Morgan Stanley grew its holdings in shares of Tyme Technologies by 187.8% in the second quarter. Morgan Stanley now owns 139,579 shares of the company’s stock worth $170,000 after purchasing an additional 91,081 shares during the last quarter. Paloma Partners Management Co bought a new position in shares of Tyme Technologies in the second quarter worth approximately $238,000. Bank of New York Mellon Corp grew its holdings in shares of Tyme Technologies by 5.9% in the second quarter. Bank of New York Mellon Corp now owns 306,199 shares of the company’s stock worth $374,000 after purchasing an additional 17,173 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Tyme Technologies in the first quarter worth approximately $27,000. Finally, BNP Paribas Arbitrage SA bought a new position in shares of Tyme Technologies in the first quarter worth approximately $46,000. 18.57% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have recently issued reports on the company. Zacks Investment Research raised Tyme Technologies from a “hold” rating to a “buy” rating and set a $1.00 price objective on the stock in a report on Friday, August 16th. HC Wainwright assumed coverage on Tyme Technologies in a report on Monday, August 12th. They set a “buy” rating on the stock.

Tyme Technologies Company Profile

Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.

See Also: Net Margin – Understanding the Different Kinds of Profit

Insider Buying and Selling by Quarter for Tyme Technologies (NASDAQ:TYME)

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.